REFRENCES
Ahsani, Z., Mohammadi‑Yeganeh, S., Kia, V., Karimkhanloo, H., Zarghami
,N., Paryan ,M.(2017) WNT1 gene from WNT signaling pathway is a direct
target of miR‑122 in hepatocellular carcinoma. Appl Biochem Biotechnol
181: 884‑ 897.
Akuta, N., Kawamura, Y., Suzuki, F., Saitoh ,S., Arase, Y., Kunimoto H.,
Sorin, Y., Fujiyama, S., Sezaki ,H., Hosaka, T., et al.(2016) Impact of
circulating miR‑122 for histological features and hepatocellular
carcinoma of nonalcoholic fatty liver disease in Japan. Hepatol Int 10:
647‑656.
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A.,
Jemal, A. (2018) Global cancer (statistics 2018: GLOBOCAN estimates of
incidence and mortality worldwide for 36 cancers in 185 countries. CA
Cancer J. Clin. 68, 394–424.
Cascio, S., D’Andrea, A., Ferla, R., Surmacz, E., Gulotta, E., Amodeo,
V., Bazan, V., Gebbia, N., Russo, A.(2010) miR-20b Modulates VEGF
Expression by Targeting HIF-1 Alpha and STAT3 in MCF-7 Breast Cancer
Cells. J. Cell. Physiol. 224, 242–249.
Chen
,Z., Xu,
S., Xu,
W., Huang,
J., Zhang
,GU., Lei,
L., Shao,
X., Wang,
X. (2015) Expression of cluster of differentiation 34 and vascular
endothelial growth factor in breast cancer, and their prognostic
significance, Oncol
Lett. 723-729
Cohen, P. (2001) Protein kinases-the major drug targets of the
twenty-first century. Nat. Rev. Drug Discovery 1: 309–315.
Colozza, M., de Azambuja, E., Personeni, N., Lebrun, F., Piccart, M.J.,
Cardoso, F. (2007) Achievements in Systemic Therapies in the Pregenomic
Era in Metastatic Breast Cancer. Onc. 12, 253–270.
Duc Duy ,Vo., Cathy, Staedel., Laura ,Zehnacker., Rachid,
Benhida.,Fabien ,Darfeuille., and Maria, Duca.(2014) Targeting the
Production of Oncogenic MicroRNAs with Multimodal Synthetic Small
Molecules. ACS Chem. Biol. 9, 711−721
Emile
,N.,Van Meter
Jackline
,A.,Onyango
Kelly,
A.Teske. (2020) A review of currently identified small molecule
modulators of microRNA function.
European
Journal of Medicinal Chemistry,
Volume
188, 112008
Eroles, P., Bosch, A., Pérez-fidalgo, J.A., Lluch, A. (2012) Molecular
biology in breast cancer: Intrinsic subtypes and signaling pathways.
Cancer Treat. Rev. 38, 698–707.
Fan-Wei
,Peng.,Da-Ke,
Liu.,Qing-Wen,
Zhang.,Yun-Gen
,Xu &Lei, Shi.
(2012-2016) VEGFR-2 inhibitors and the therapeutic applications thereof:
a patent review.
Expert Opinion on
Therapeutic Patents Volume 27, 2017 - 987-1004
Ferrara, N., Gerber ,H.P., LeCouter, J. (2003) The biology of VEGF and
its receptors. Nat Med. 9, 669–676.
Fox, S.B., Generali, D.G., Harris, A.L. (2007) Breast tumour
angiogenesis. Breast Cancer Res 9: 216. doi: 10.1186/bcr1796 PMID:
18190723.
Hamam, R.,Hamam, D., Alsaleh, K.A., Kassem, M.,Zaher, W., Alfayez, M.,
Aldahmash, A., Alajez, N.M.(2017) Circulating microRNAs in breast
cancer: Novel diagnostic and prognostic biomarkers. Cell Death Dis. 8,
e3045.
Holmes, K., Roberts, O. L., Thomas, A. M. & Cross, M. J. (2007)
Vascular endothelial growth factor receptor-2: Structure, function,
intracellular signalling and therapeutic inhibition. Cellular Signalling
19, 2003–2012.
Hopcraft ,S.E., Azarm, K.D., Israelow, B., Lévêque, N., Schwarz, M.C.,
Hsu, T.H., Chambers, M.T., Sourisseau, M., Semler, B.L., Evans,
M.J.(2015) Viral determinants of miR‑122‑independent hepatitis C virus
replication. mSphere 1: 1.
Howlader, N., Noone, A. M.,Krapcho, M., Neyman, N., Aminou, R.,
ltekruse, S. F.,Kosary, C. L., Ruhl, J., Tatalovich, Z., Cho, H., et al.
(2009) SEER Cancer Statistics Review,1975-2009, Vintage Populations.
Natl. Cancer Inst. 2012. Bethesda, MD.
Hu, F., Xu, P., Sun, B., Xiao, Z.(2017) Differences in the MicroRNA
profiles of subcutaneous adipose ‑ derived stem cells and omental
adipose ‑derived stem cells. Gene 625: 55 ‑63.
Hu, J., Cheng, Y., Li, Y., Jin, Z., Pan, Y., Liu, G., Fu, S., Zhang, Y.,
Feng, K., Feng, Y.(2014) microRNA-128 Plays a Critical Role in Human
Non-Small Cell Lung Cancer Tumourigenesis, Angiogenesis and
Lymphangiogenesis by Directly Targeting Vascular Endothelial Growth
Factor-C. Eur. J. Cancer. 50, 2336–2350.
Isidro,
X., Perez‐Añorve,
Claudia
,H., Gonzalez‐De ,
Rosa., Ernesto
Soto‐Reyes., Fredy,
O.,
Beltran‐Anaya, Oscar
Del
Moral‐Hernandez, Marisol
Salgado‐Albarran, et al. (2019) New insights into radioresistance in
breast cancer identify a dual function of miR‐122 as a tumor suppressor
and oncomiR.
Mol
Oncol. 13, 1249–1267.
Jia, D., Hasso, S.M., Chan, J., Filingeri ,D., D’Amore, P.A., Rice, L.,
et al.( 2013) Transcriptional repression of VEGF by ZNF24: mechanistic
studies and vascular consequences in vivo. Blood 121: 707–715. doi:
10.1182/blood-2012-05-433045 PMID: 23212515.
Kian, R., Moradi, S.,Ghorbian, S. (2018) Role of components of microRNA
machinery in carcinogenesis. Exp. Oncol. 40, 2–9.
Lala, P. K., Nandi, P., Majumder, M. (2018) Roles of Prostaglandins in
Tumor Associated Lymphangiogenesis with Special Reference to Breast
Cancer. Cancer Metastasis Rev. 37, 1.
Lazarus, H., Tegeler, W., Mazzone, H. M., Leroy, J. G., Boone, B. A., &
Foley, G. E.(1966) Determination of sensitivity of individual biopsy
specimens to potential inhibitory agents: evaluation of some explant
culture methods as assay systems. Cancer Chemotherapy Reports, 50(8),
543–555.
Liu, X.,Guan, Y., Wang, L.,Niu, Y.(2017) MicroRNA-10b Expression in
Node-Negative Breast Cancer-Correlation with Metastasis and
Angiogenesis. Oncol. Lett. 14, 5845–5852.
Lou, W., Liu, J., Gao, Y.,Zhong, G., Chen, D., Shen, J., Bao, C., Xu,
L., Pan, J., Cheng, J.,et al. (2017) MicroRNAs in Cancer Metastasis and
Angiogenesis. Oncotarget 8, e115787.
Maae, E., Olsen, D.A., Steffensen, K.D., Jakobsen, E.H., Brandslund, I.,
Sørensen, F.B., et al. (2012). Prognostic impact of placenta growth
factor and vascular endothelial growth factor A in patients with breast
cancer. Breast Cancer Res Treat 133: 257–265. doi:
10.1007/s10549-012-1957-0 PMID: 22270936.
Maierthaler, M., Benner, A., Hoffmeister, M., Surowy, H., Jansen, L.,
Knebel, P., Chang‑Claude, J., Brenner, H., Burwinkel, B.(2017) Plasma
miR‑122 and miR‑200 family are prognostic markers in colorectal cancer.
Int J Cancer 140: 176‑187.
Musumeci, F., Radi, M., Brullo, C., et al. (2012) Vascular endothelial
growth factor (VEGF) receptors: drugs and new inhibitors. J Med
Chem. 55(24):10797–10822.
Olsson, A. K., Dimberg, A., Kreuger, J., Claesson-Welsh L. (2006) VEGF
receptor signalling - in control of vascular function. Nat Rev Mol Cell
Biol. 7:359–371
Otrock, Z.K., Mahfouz, R.A.R., Makarem, J.A., Shamseddine, A.I. (2007)
Understanding the Biology of Angiogenesis: Review of the most Important
Molecular Mechanisms. Blood Cells Mol. Dis. 39, 212–220.
Pan, C., Wang, X., Shi, K., Zheng, Y., Li, J., Chen, Y., Jin, L., Pan
,Z.(2016) miR‑122 reverses the doxorubicin ‑resistance in hepatocellular
carcinoma cells through regulating the tumor metabolism. PLoS One 11:
e0152090.
Pyakurel, D., Karki, S., & Agrawal, C. (2014) A study on microvascular
density in breast carcinoma. Journal of Pathology of Nepal, 4(7),
570-575.
Qin, H., Sha, J., Jiang, C., Gao, X., Qu ,L., Yan, H., Xu, T., Jiang,
Q., Gao, H.(2015) miR‑122 inhibits metastasis and epithelial‑mesenchymal
transition of non‑small‑cell lung cancer cells. Onco Targets Ther 8:
3175‑3184.
Ran, S., Volk, L., Hall, K., Flister, M.J.(2010) Lymphangiogenesis and
Lymphatic Metastasis in Breast Cancer. Pathophysiology 17, 229–251.
Sebolt-Leopold, J.S .(2006) Mechanisms of drug inhibition of signalling
molecules. Nature 441: 457-462
Shibuya, M.(2011) Vascular Endothelial Growth Factor (VEGF) and its
Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti-
and Pro-Angiogenic Therapies. Genes Cancer 2, 1097–1105.
Song, S., Ajani, J.A.(2013) The role of microRNAs in cancers of the
upper gastrointestinal tract. Nature Rev. Gastroenterol. Hepatol. 10,
109–118.
Svoronos, A.A., Engelman, D.M., Slack, F.J.(2016) Oncomir or tumor
suppressor? The duplicity of microRNAs in cancer. Cancer Res. 76,
3666–3670.
Tao, L., Chu, L., Wang, L.I., Moy, L., Brammer, M., Song, C., Green, M.,
Kurian, A.W., Gomez, S., Clarke, C.A. (2016) Occurrence and outcome of
de novo metastatic breast cancer by subtype in a large, diverse
population. Cancer Causes Control. 27, 1127–1138.
Uzzan, B., Nicolas, P., Cucherat, M., Perret, G.Y. (2004) Microvessel
density as a prognostic factor in women with breast cancer: a systematic
review of the literature and meta-analysis. Cancer Res ;64:2941^55.
Von Felden, J., Heim ,D., Schulze, K., Krech, T., Ewald, F., Nashan, B.,
Lohse, AW., Wege, H.(2017) High expression of micro RNA‑135A in
hepatocellular carcinoma is associated with recurrence within 12 months
after resection. BMC Cancer 17: 60, 2017
Wang, C., Zheng, X ., Shen, C., Shi, Y.(2012) MicroRNA-203 suppresses
cell proliferation and migration by targeting BIRC5 and LASP1 in human
triple-negative breast cancer cells. J Exp Clin Cancer Res. 31: 58.
Williams, J. I., Weitman, S., Gonzalez, C. M., Jundt, C. H., Marty, J.,
Stringer, S. D., Von Hoff, D. D.( 2001) Squalamine treatment of human
tumors in nu/nu mice enhances platinum-based chemotherapies. Clinical
Cancer Research: An Official Journal of the American Association for
Cancer Research, 7(3), 724–733.
Young,
D.D., Connelly,
C.M., Grohmann,
C., Deiters,
A.
Small
molecule modifiers of MicroRNA miR-122 function for the treatment of
hepatitis C Virus infection and hepatocellular carcinoma..
Journal
of the American Chemical Society 132, (23), 7976-7981
Zhong
,Hua., Qing
,Lv., Wenbin,
Ye., Chung-Kwun
Amy Wong,
and Yaou
,Zhang. (2006)
PLoS One.
2006; 1(1): e116.
Zorgetto ,V,A., Silveira ,G.G., Oliveira-Costa, J.P., Soave ,D.F.,
Soares, F.A., and Ribeiro-Silva, A.(2013) The relationship between
lymphatic vascular density and vascular endothelial growth factor A
(VEGF-A) expression with clinical-pathological features and survival in
pancreatic adenocarcinomas. Diagn Pathol. 8:170.